Articles related to DRUG SAFETY & INTERACTIONS

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

The FDA classified a recall of thyroid tablets USP 30 mg as Class I after identification of a superpotent product lot. The recall affects 1,955 bottles and carries risk of serious adverse health consequences, making prompt inventory review and product removal necessary.

A case report describes duodenal ulcer perforation in a woman receiving tirzepatide for weight loss, occurring shortly after dose escalation, though important confounders prevent conclusions about a causal drug relationship.

Semaglutide use before or during pregnancy was associated with greater gestational weight gain and several adverse outcomes in a retrospective cohort, although similar findings among former users complicate attribution to direct fetal exposure.

The FDA classified a recall of dorzolamide and timolol ophthalmic solution as a Class II event after reports of defective containers, affecting a specific lot used to treat glaucoma and ocular hypertension.

The FDA classified a recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief as a Class II event after the manufacturer identified sterility concerns and potential contamination affecting a single lot.